The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by MMS Holdings and MichBio.org

This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm. The knowledge shared in this presentation echoes the regulatory guidance’s for use of RWE. Evolving standards that are necessary to make the most out of RWD, demonstration projects, and first-hand experience with some technical tools will be discussed. Combining it all together should provide the tools and knowledge to navigate more confidently through this less explored, but complex landscape of RWD and RWE.

Speakers include:

  • Narasimha Ayyalas, Manager, Statistical Programming, MMS Holdings
  • Aditya Gadiko, Senior Clinical Programmer, MMS Holdings
  • Susheel Arkala, Manager, Statistical Programming, MMS Holdings
  • Chris Hurley, Associate Director, Data Sciences, MMS Holdings
  • Ravi Yandamuri, Principal Clinical Programmer, MMS Holdings

Suggested For You

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations